Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Prognostic value of patient reported outcomes (PROs) in advanced gastroesophageal cancer (GO): A systematic review.
Authors
Sayeda Kamrun Naher
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
Sayeda Kamrun Naher , Peter S. Grimison , Ho Wai Derrick Siu , Rebecca Mercieca-Bebber , Martin R. Stockler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.251
Abstract #
251
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Quality Care Symposium
Methods for alerting clinicians to concerning symptom questionnaire responses during cancer care: Approaches from two randomized trials (STAR, AFT-39 PRO-TECT).
First Author: Angela M. Stover
Poster
2017 ASCO Annual Meeting
Patient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK+ non–small cell lung cancer (NSCLC).
First Author: Corey J. Langer
Poster
2024 ASCO Annual Meeting
Relationship between cognitive and emotional domains of prognostic awareness with quality of life and psychological distress in patients with advanced cancer.
First Author: Claire Greydanus
Poster
2023 ASCO Quality Care Symposium
Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.
First Author: Mansoor Raza Mirza